APRELIEVA 150MG ( Fosaprepitant Dimeglumine for Injection 150mg )

APRELIEVA 150 mg contains Fosaprepitant Dimeglumine, a neurokinin-1 (NK1) receptor antagonist. It is a prodrug of aprepitant and works by blocking substance P in the brain, thereby preventing chemotherapy-induced nausea and vomiting (CINV), especially delayed emesis.

Fosaprepitant is used for prevention of:

1. Chemotherapy-Induced Nausea and Vomiting (CINV)
    – Associated with highly emetogenic chemotherapy (HEC)
    – Associated with moderately emetogenic chemotherapy (MEC)

It is used in combination with:

•  A 5-HT3 receptor antagonist (e.g., ondansetron)

•  Dexamethasone

Common side effects:

•  Fatigue

•  Hiccups

•  Headache

•  Constipation or diarrhea

Injection-site reactions:

•  Pain

•  Erythema

•  Phlebitis

Serious side effects (rare):

•  Hypersensitivity reactions

•  Anaphylaxis

Monitor for infusion-site reactions.

Standard adult dose:

•  150 mg IV single dose

•  Administered 30 minutes before chemotherapy on Day 1

 Replaces 3-day oral aprepitant regimen.

NOTE: This medicine should be taken only under a doctor’s supervision.